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A B S T R A C T
One attractive approach to increase the aqueous solubility and thus the bioavailability of poorly soluble
drugs is to formulate them in their amorphous state since amorphous compounds generally exhibit
higher apparent solubilities than their crystalline counterparts. In the current work, mesoporous
magnesium carbonate was used to stabilise the amorphous state of the model substance ibuprofen.
Crystallisation of the drug was completely supressed in the formulation, resulting in both a higher
apparent solubility and a three times faster dissolution rate of the drug where the drug release was
shown to be diffusion controlled. It was also shown that the formulation is stable for at least three months
when stored at 75% relative humidity. The simple synthesis together with a high loading capacity and
narrow pore size distribution of the mesoporous magnesium carbonate is foreseen to offer great
advantages in formulations of poorly soluble drugs.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Over recent decades, the poor aqueous solubility of many active
pharmaceutical ingredients (APIs) has been one of the most
challenging issues for the pharmaceutical industry. About 40% of
newly marketed drugs have poor solubility and 80–90% of drug
candidates in the R&D pipeline fail because of solubility problems
(Babu and Nangia, 2011; Jia, 2005; Serajuddin, 1999). These drugs
with poor aqueous solubility subsequently have low bioavailabili-
ty, which can limit their therapeutic efﬁcacy. To circumvent this
problem, a number of different strategies have been developed,
including crystalline salt formulations, API particle reduction, use
of solubilisers, co-ground mixtures, and pro-drugs (Brouwers et al.,
2009). The success of a formulation strategy depends on both the
chemical nature of the drug and practical processing issues. For
example, strongly acidic and basic substances can be formulated as
salts while weak acids and bases cannot, whereas reduction of the
API particle size can lead to build-up of static charges imposing
handling difﬁculties for certain substances (He, 2009).
Since a high number of therapeutically promising, poorly soluble
APIs never reach the patient due to lack of suitable formulation
methods, there is still a high unmet need for new strategies in this
area. One recently embarked on, and seemingly attractive, approach
is to stabilise such APIs in their amorphous state since, despite the
higher energy and metastability associated with this state,
amorphous drugs generally exhibit higher apparent solubility than
the crystalline form of the same substance (Brouwers et al., 2009;
Galia et al., 1998; Xu et al., 2013). However, because of their
metastable nature, amorphous APIs are driven by thermodynamics
to crystallise, depending on factors like the glass transition
temperature (Tg) and moisture content of the formulation (Yoshioka
and Aso, 2007). Thus, the amorphous API needs to be stabilised in
the formulation in order to prevent crystallisation. Typically,
organic polymers like polyethylene glycol (PEG) and polyvinyl
pyrroline (PVP) are used in solid dispersions for this purpose. The
complex polymer network acts by reducing the mobility of the drug
molecules (Konno et al., 2008; Rawlinsonet al., 2007). However, this
approach is associated with difﬁculties in the industrial
manufacturing processes and problems with the chemical stability
of the products (Qian et al., 2010; Taylor and Zograﬁ, 1997).
Nonetheless, the emergence of nanotechnology in the last
decades has provided novel solutions for drug delivery in most
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pharmaceutical formulation areas (Fadeel et al., 2010; Mihranyan
et al., 2012), including the area targeting the stabilisation of
amorphous APIs. It has been found that mesoporous structures
(with pore diameters between 2 and 50 nm) are able to effectively
suppress the crystallisation of amorphous substances via
geometrical constraints, and also as a result of changes in
nucleation mechanisms and kinetics inside the small pores and
the interaction between the API and the pore walls (Rengarajan
et al., 2008), which can induce a crystalline-to-amorphous phase
transformation (Qian and Bogner, 2011). This effect is more
pronounced on surfaces featuring high curvature and on those
with permanent dipoles, which can induce polarization or form
dipole–dipole interactions (Qian et al., 2011). The phenomenon
was ﬁrst observed in 1984 when Nakai et al. (Nakai et al., 1984)
saw an anomaly in the melting endotherm and the X-ray
diffraction pattern of organic compounds that were mixed
together with controlled-pore glass beads. It was suggested that
this anomaly was due to amorphisation of the organic molecules
under study (i.e. benzoic acid), which had diffused into the voids
between the glass beads and existed there in an amorphous state.
It was later shown that this type of amorphisation is pronounced
in pores with diameters smaller than 50 nm (Nakai et al., 1989). In
2001, the mesoporous silica MCM-41 was proposed as a drug
delivery vehicle (Vallet-Regi et al., 2001) and since then different
mesoporous silicas have been found useful for improving the
solubility of several pharmaceutical compounds (such as itraco-
nazole, atazanavir and ibuprofen (Bras et al., 2011; Heikkila et al.,
2007; Mellaerts et al., 2007; Xia et al., 2012)) because of
conservation of the amorphous state of the incorporated API.
Recent publications have also shown good correlations between
improved in vitro solubility and improvements in the bioavail-
ability of drugs formulated in mesoporous materials (Wang et al.,
2012; Xia et al., 2012). However, the mesoporous silica industry
struggles with high manufacturing costs due to expensive silica
sources and surfactants used in the fabrication, as well as
environmental concerns related to the often toxic surfactants
needed as pore-forming templates in the synthesis (Gerardin
et al., 2013). Mesoporous silica is not yet available in bulk
quantities and the price for MCM-41 available via e.g. Sigma–
Aldrich is presently 20,000 s kg1 (2014)1. Mesoporous silicon
produced via etching of crystalline silicon also appears to
conserve amorphous APIs, but this type of material is also
associated with high production costs and difﬁculties with large
scale manufacturing (Xu et al., 2013).
In connection to the above, it should be pointed out that the
mesoporous forms of silica and silicon should not be confused with
colloidal silica based on aggregated nanoparticles forming rather
ﬂuffy structures. Whereas the latter is commonly used in
pharmaceutical formulations as, e.g. anti-caking agent, adsorbent
or disintegrant, it lacks the pore structure of the former and has not
been shown to have the ability to work as solubility enhancers of
poorly soluble substances.
As an alternative to mesoporous silica, we have recently
proposed the use of a mesoporous type of vaterite (calcium
carbonate) for the stabilisation of amorphous drugs (Forsgren
et al., 2013a). The studied vaterite had a smaller pore volume and
less well-deﬁned pore size than mesoporous silica but is already
listed as ‘generally recognized as safe’ (GRAS) by the FDA, and it can
be produced from inexpensive raw materials in a simple synthetic
process, which makes it an interesting drug stabiliser candidate.
Vaterite had a stabilising effect on the incorporated amorphous
API, which resulted in higher solubilities and faster dissolution
rates for both celecoxib and ketokonazol (Forsgren et al., 2013a).
However, the vaterite carrier proved to be unstable when exposed
to humidity and complete suppression of crystallisation of the
incorporated API was not obtained at higher drug loading levels.
Other recent publications also show the possibility of using
materials like mesoporous alumina and titanium zirconium oxide
for the purpose of stabilising amorphous drugs (Kapoor et al.,
2009; Wang et al., 2013), however, the FDA does not list these
materials as GRAS, which is expected to complicate the route
toward regulatory approval for such materials as pharmaceutical
excipients.
Recently, we disclosed the synthesis and characterization of a
novel mesoporous type of magnesium carbonate, named Upsalite,
which can be synthesised using MgO, methanol and CO2 as raw
materials without using surfactants as pore-forming agents
(Forsgren et al., 2013b; Frykstrand et al., 2014). Just like calcium
carbonate, magnesium carbonate is also GRAS listed and the
current work investigates the ability of Upsalite to enhance the
solubility and at the same time provides high loading capacity and
stability of poorly soluble APIs. Ibuprofen, a well-known, non-
steroidal anti-inﬂammatory drug with limited aqueous solubility is
used as model API in this study.
2. Materials and methods
2.1. Materials
Magnesium oxide (MgO) and ibuprofen (IBU) were obtained
from Sigma–Aldrich, Sweden. Methanol and ethanol were
purchased from VWR International, Sweden. CO2 was obtained
from AirLiquide, Sweden. All chemicals were used as received.
2.2. Synthesis of Upsalite
Upsalite was synthesised as described previously (Forsgren
et al., 2013b; Frykstrand et al., 2014). Brieﬂy, 170 g of MgO and 2.5 L
CH3OH were mixed at 500 rpm in a 5 L Ecoclave pressure reactor
from Büchi. The reactor was pressurised with 3 bar CO2 and the
reaction was carried out at 55 C. After four days, the temperature
was lowered to room temperature and the reactor was depres-
surised. The product was dried at 75 C in a vacuum oven for three
days and then calcined at 250 C for 6 h. Calcination is needed for
complete decomposition of the organic intermediates formed in
the reaction carried out in the pressure reactor (Frykstrand et al.,
2014). When the calcination is performed at temperatures below
350 C, magnesium carbonate is formed but at higher temper-
atures the carbonate will decompose into MgO and CO2. After
calcination, the obtained material was in the shape of white,
centimetre sized particles that were grinded down to a smaller
particle size using a mortar.
2.3. Drug loading procedure
IBU was incorporated into the Upsalite via a soaking method:
203.2 mg IBU was dissolved in 50 mL ethanol and then 642.7 mg of
Upsalite was added to the solution. The mixture was placed on an
orbital shaker at 100 rpm at room temperature for 24 h to allow for
diffusion of IBU into the Upsalite. Subsequently, the suspension
was dried in an oven at 70 C to evaporate the solvent.
2.4. Characterisation
2.4.1. X-ray powder diffraction (XRD)
XRD analysis was performed with a D5000 diffractometer
(40 kV, 40 mA, Siemens/Bruker) using Cu-Ka radiation
(l = 0.154 nm). Samples were ground in a mortar and put on
silicon sample holders with zero background prior to analysis.1 www.sigmaaldrich.com on 22 Jan 2014.
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2.4.2. Fourier transform infrared spectroscopy (FTIR)
FTIR studies were carried out in a Bruker FTS66v/s spectrometer
with an attenuated total reﬂectance (ATR) sample holder. All FTIR
spectra were collected at a spectrum resolution of 4 cm1 with 50
scans over a range of 4000–400 cm1. A background scan was
acquired before scanning the samples.
2.4.3. N2 sorption analysis
Gas sorption isotherms were obtained using an ASAP 2020 from
Micromeritics, operated at 196 C. Prior to analysis, the samples
were degassed under vacuum at 90 C for 12 h. The speciﬁc surface
area (SSA) was calculated using the multipoint Brunauer–Emmett–
Teller (BET) method (Brunauer et al., 1938) for adsorption values in
the relative pressure range between 0.05 and 0.3, while the pore
size distribution was calculated based on the density functional
theory (DFT) method using the model for N2 at 196 C. The total
pore volume was obtained from single point adsorption at a
relative pressure P/P0 1. These calculations, including calcula-
tions of the errors of the SSA values, were all performed using the
ASAP 2020 (Micromeritics) software.
2.4.4. Thermal gravimetric analysis (TGA)
TGA was carried out on a Mettler Toledo, model TGA/SDTA851e,
under airﬂow in an inert aluminium cup. The samples were heated
from room temperature to 600 C at a heating rate of 3 C min1.
2.4.5. Differential scanning calorimetry (DSC)
DSC was performed on a DSC Q2000 instrument from TA
instruments using Exstar software. Samples of 3.5–5.5 mg were
weighed into 5 mm aluminium pans and sealed. Samples were ﬁrst
cooled to 35 C and then heated to 150 C at a heating rate of
3 C min1. The instrument was calibrated for the melting point and
heat of fusion (Tm [C] and DHm [mJ mg1]) of indium (156.6 C and
28.4 mJ mg1).
2.4.6. Scanning electron microscopy (SEM)
SEM imaging of the Upsalite was performed with a Leo 1550
FEG microscope (Zeiss, Oberkochen, Germany) equipped with an
in-lens detector. A thin gold/palladium layer was sputtered onto
samples prior to analysis to avoid charging of the samples. The
analysis was performed at 1.5 kV acceleration voltage.
2.4.7. Drug-release measurement
The release of IBU was measured in a USP-2 dissolution bath
(Sotax AT7 Smart, Sotax AG, Switzerland) equipped with 1000 mL
vessels (37 C, 50 rpm). Samples with a total drug content of
17.5 mg IBU were placed in vessels containing 500 mL phosphate
buffer (pH 6.8). Aliquots of 3 mL were withdrawn from each vessel
at regular intervals for 125 min and the drug concentration in the
liquid samples was analysed using UV/visual absorbance spectros-
copy at 219.4 nm (1650PC, Shimadzu Corporation, Kyoto, Japan).
Measurements were made in triplicates on pure IBU crystals and
IBU-loaded Upsalite (Upsalite-IBU) and the mean concentration
values and corresponding standard deviations were calculated.
2.4.8. Long-term stability test
An amount of the Upsalite-IBU sample was stored in a
desiccator at room temperature and 75% RH (obtained with a
saturated mixture of water and NaCl) for three months. The sample
was then analysed with XRD and DSC to investigate whether a
humid atmosphere induced crystallisation of the incorporated IBU.
Upsalite without IBU was also stored under the same conditions to
examine whether the humidity affected the carrier material.
3. Results and discussion
Fig. 1 presents a photograph of the as-synthesised Upsalite
particles and SEM images of grounded Upsalite particles. The
photograph shows white and millimetre to centimetre-sized
Fig. 1. Left panel: a photograph of the as-synthesised Upsalite. Right panels: SEM images of grinded Upsalite particles.
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particles of irregular shape typical for the amorphous magnesium
carbonate in Upsalite. The SEM images display that whereas
grinding reduced the particle size down to a few hundred
micrometre, the particle shape remained irregular.
The magnesium carbonate component in Upsalite is evident
from the transmission FTIR spectra of the material, see Fig. 2,
where bands observed at 850 cm1, 1100 cm1 and 1400 cm1
correspond to the carbonate group (Raade, 1970) and the
absorbance band at 3440 cm1 corresponds to adsorbed water.
No new absorbance bands were observed for the Upsalite-IBU
sample in addition to those present in the spectra from the free IBU
and the empty Upsalite samples, which indicate that the IBU in
Upsalite was physisorbed rather than chemisorbed to the surface
of the pore walls in Upsalite.
Fig. 2 also displays the XRD patterns for Upsalite obtained after
calcination as well as for free IBU and Upsalite-IBU. The peaks in
the XRD patterns for Upsalite and Upsalite-IBU correspond to
unreacted MgO (Forsgren et al., 2013b). The lack of other peaks in
these samples shows that the magnesium carbonate component in
Upsalite is amorphous, in agreement with previous studies
(Forsgren et al., 2013b; Frykstrand et al., 2014; Pochard et al.,
2014), and also that the IBU incorporated in the Upsalite-IBU
sample is amorphous.
The lack of crystalline IBU in the Upsalite-IBU sample was also
evident from the DSC curves displayed in Fig. 3. The endothermic
event at 78 C for the free IBU corresponds to the melting point for
the crystalline structure. The complete lack of an endothermic
event at the same temperature for the Upsalite-IBU sample
conﬁrms that the incorporated IBU was not present in a crystalline
state inside the pores. No peaks corresponding to any endo- or
exothermic events were detected in the DSC scan between 35 C
and 150 C for the Upsalite-IBU sample. The XRD and DSC data
prove that the mesoporous structure in Upsalite completely
suppresses crystallisation of the incorporated IBU. Further, since
there were no signs of crystalline IBU in the Upsalite-IBU sample, it
can be concluded that only an insigniﬁcant, if any, amount of IBU
resides on the outer surface of the carrier particles. The outer
surface area of the carrier particles is negligible compared to the
internal surface area and only has a limited ability to interact with
the IBU and thus suppress crystallisation of the substance. This
result stands in contrasts to studies on mesoporous silica where
crystalline ibuprofen is found on the surface on the particles when
the drug loading is carried out using similar impregnation methods
(Bras et al., 2011; Shen et al., 2010; Szegedi et al., 2012). Hence, the
Upsalite displays a superior ability to adsorb ibuprofen into the
porous structure or the particles.
Fig. 3. Left panel: DSC curves for the studied samples. The absence of a melting peak for the Upsalite-IBU sample shows that the incorporated IBU lacks a lattice energy
associated with a crystalline structure, hence, the IBU is in an amorphous state. Right panel: TGA curves for the studied samples.
Fig. 2. Left panel: FTIR absorption spectrums for the samples under study. In the spectrum of Upsalite, the three visible bands at 1440 cm1, 1100 cm1 and 850 cm1 are
all due to vibrations of the CO3 group. Right panel: XRD patterns for the samples under study. The peaks at 37, 43 and 62 in the Upsalite and Upsalite-IBU samples
correspond to unreacted MgO residing in the carbonate structure. The halo at 15–20 in Upsalite-IBU indicates an amorphous character of the incorporated ibuprofen.
188 P. Zhang et al. / International Journal of Pharmaceutics 472 (2014) 185–191
No signs of crystallisation of the IBU incorporated in Upsalite
were detected with XRD and DSC stability testing after the sample
had been stored at 75% RH for three months at room temperature.
Nor were there any signs of crystallisation of the amorphous
magnesium carbonate component in the Upsalite after exposure to
the humid atmosphere. This indicates good stability for the
proposed formulation, even under tough conditions, since
moisture is a well-known plasticiser of pharmaceutical formula-
tions and adsorbed water can decrease the Tg of many formulations
and allow sufﬁcient drug molecule mobility to induce crystal-
lisation of amorphous drugs (Ahlneck and Zograﬁ, 1990; Andronis
et al., 1997; Qian et al., 2012).
After loading Upsalite with IBU, TGA was carried out to
investigate the degree of drug loading in the carrier. The TGA
curves for Upsalite, free IBU and Upsalite-IBU are presented in
Fig. 3. As evident from the ﬁgure, free IBU evaporated at 200 C
while the magnesium carbonate in Upsalite decomposed into MgO
and CO2 at 370 C. Two distinct regions of weight loss, at 330 C
and 420 C, were observed for the Upsalite-IBU sample; the ﬁrst,
clearly associated with the evaporation of IBU, corresponds exactly
to the 24 wt% of IBU used in the preparation of the sample and the
second with the decomposition of the magnesium carbonate.
Interestingly, the evaporation temperature for the incorporated
IBU was increased by about 140 C compared to the free substance.
A similar phenomenon has been observed previously for IBU as
well as for ketoprofen incorporated in mesoporous materials
(Hillerstrom et al., 2009; Li-Hong et al., 2013; Moritz and Laniecki,
2012; Wang et al., 2006). The increase in evaporation temperature
could be explained by capillary forces in the pores, as described by
the Kelvin equation:
ln
P
P0ðTÞ ¼ 
2g
RK
VM
RT
(1)
where P is the equilibrium vapour pressure, P0(T) is the saturation
vapour pressure at the given temperature, g is the surface tension,
VM is the molar volume of the liquid, RK is the Kelvin radius of the
liquid curvature and R is the universal gas constant. According to
the Kelvin equation, lower pressures or higher temperatures are
needed to evaporate liquids from nanometre-sized pores com-
pared to a free liquid; this is a result of capillary forces acting on the
liquid and forcing it to remain in a condensed state in the pores,
leading to the increased evaporation temperature for the
incorporated IBU.
The pore volume and SSA of the studied samples are given in
Table 1 while the pore size distributions obtained from the N2
sorption analysis are displayed in Fig. 4. Both SSA and pore size
distribution of unloaded samples are similar to those measured
previously for calcined Upsalite (Frykstrand et al., 2014). From the
ﬁgure and the table, respectively, it is evident that the pore
diameter in the Upsalite-IBU sample was reduced by about 2 nm
compared to the unloaded Upsalite whereas the pore volume was
reduced to half. Since the diameter of an IBU molecule is about
1 nm (Vallet-Regi et al., 2001), this indicates that the IBU molecules
were arranged in a monolayer along the pore walls of Upsalite
rather than in clustered multilayer structures. The pore volume
data also suggest that the 24 wt% IBU loading degree was about half
of the maximum drug loading capacity of Upsalite. More drug is
expected to enter the carrier particles if the amount of drug
employed in the loading procedure is increased or if other loading
techniques are employed; such as spray drying which has been
shown to improve the loading capacity of mesoporous silica
(Shen et al., 2010).
The dissolution proﬁles of free IBU and IBU incorporated in
Upsalite are shown in Fig. 5. Clearly, the dissolution of the
amorphous IBU inside Upsalite was more rapid than that of the free
substance. During the ﬁrst 5 min, the dissolution rate for the IBU in
the Upsalite-IBU sample was three times higher than that for the
free substance; similarly, 50% of the IBU was dissolved and released
from the Upsalite carrier within 12 min while it took 30 min for the
free substance to reach the same dissolution level. The dissolution
of IBU in its free form levelled out at 75% after about 80 min,
corresponding to a concentration of IBU in the dissolution media of
27 mg L1. In contrast, the dissolution of the amorphous IBU from
Upsalite continued beyond 85%, corresponding to a concentration
of 30 mg L1 IBU. This shows that the apparent solubility of the
drug could be increased by at least 11% under the given conditions
when it was formulated with Upsalite. One way Anova analysis
gave that this difference was signiﬁcant at p < 0.05 level
[F(1,4) = 22.4, p = 0.009]. However, in the present study, the amount
of drug used in the release experiments was close to the solubility
limit of free ibuprofen under the given conditions and an even
higher supersaturated state of the drug is expected if a larger
amount of sample is used. This will be investigated in future
studies. In order to examine the release mechanism of IBU from the
Upsalite particles, the release data was ﬁtted with the semi-
empirical Korsmeyer–Peppas equation:
Mt
M1
¼ ktn (2)
where Mt/M1 is the released fraction of the drug, k is a kinetic
constant, t is the release time and n is the diffusional exponent
characteristic of the release mechanism. The Korsmeyer–Peppas
equation is valid for the ﬁrst 60% of the released amount of drug
and can be used to analyse the release mechanism from non-
swelling and swelling matrices (Ritger and Peppas, 1987a,b,b). For
non-swelling systems it can be used to discriminate between
Fickian diffusion, non-Fickian (anomalous) transport and zero-
order release mechanisms: for a monodisperse sample of spherical
particles, an n-value of 0.43 represents purely Fickian diffusion
Table 1
Speciﬁc surface area (SSA) and total pore volume (Vpore) of the Upsalite samples.
Sample SSA (m2 g1) Vpore (cm3g1)
Upsalite 349  0.63a 0.83
Upsalite-IBU 245  1.17a 0.39
a The values are based on single measurements and the errors were obtained
using the ASAP 2020 (Micromeritics) software.
Fig. 4. Pore size distributions for the empty and the IBU-ﬁlled Upsalite.
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while an n-value of 1.0 represents a zero-order release mechanism.
Any n-value between 0.43 and 1.0 represents some type of
combination of release mechanisms or non-Fickian transport
(Ritger and Peppas, 1987a). Since the Upsalite particles of the
current work have been grinded and the aspect ratio, as
determined from the SEM images, is fairly low the particles can
be regarded as spherical. When the release data for the Upsalite-
IBU sample was ﬁtted with the Korsmeyer–Peppas equation, it
showed good correlation (R2 > 0.99) and an n-value of 0.29 was
obtained, see Fig. 5. This behaviour witnesses of a release
mechanism that is exclusively diffusion limited from particles
with a wide size distribution (Ritger and Peppas, 1987a). The wide
particle distribution is expected since the Upsalite particles were
not sieved after grinding. In the future, it would thus be of interest
to investigate the release of various substances from samples with
well-deﬁned particle sizes to analyse how the release time can be
tailored by controlling the particle size.
4. Conclusions
As evident from the current work, the mesoporous magnesium
carbonate Upsalite provides a great potential for the development
of new drug formulations of APIs with poor aqueous solubility.
Crystallisation of the BCS class II substance ibuprofen was
completely suppressed by the mesoporous structure of Upsalite,
leading to both faster dissolution rate and increased solubility
compared to the crystalline drug in free form, and the formulation
was stable for at least three months when stored at 75% relative
humidity. The easy fabrication of Upsalite and the fact that its
constituent magnesium carbonate is already GRAS-listed are
expected to offer advantages in the considered application area
compared to e.g. mesoporous silica and mesoporous silicon, while
the stability and drug loading capacity of the material are superior
to those previously evaluated mesoporous vaterite (calcium
carbonate). The diffusion limited release of the incorporated
substance provides means to control the release rate by adjusting
the particle size of the carrier particles, something that will be
investigated in future works.
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